Optimising patient outcomes: temporal trends in remission rates of rheumatoid arthritis patients in the Australian OPAL dataset between 2009 and 2022

Geoffrey Littlejohn; Nithila Anbumurali; Catherine O'Sullivan; Tegan Smith; Kathleen Tymms; Paul Bird; David Nicholls; Hedley Griffiths

doi:10.1007/s10067-024-06967-8

Back

Optimising patient outcomes: temporal trends in remission rates of rheumatoid arthritis patients in the Australian OPAL dataset between 2009 and 2022

Journal article

Open access

Peer reviewed

Optimising patient outcomes: temporal trends in remission rates of rheumatoid arthritis patients in the Australian OPAL dataset between 2009 and 2022

Geoffrey Littlejohn, Nithila Anbumurali, Catherine O'Sullivan, Tegan Smith, Kathleen Tymms, Paul Bird, David Nicholls and Hedley Griffiths

Clinical Rheumatology, Vol.43, pp.1823-1832

2024

DOI: https://doi.org/10.1007/s10067-024-06967-8

PMCID: PMC11111498

PMID: 38634966

Files and links (1)

pdf

s10067-024-06967-81.19 MBDownload View

Published Version Open Access CC BY V4.0

Abstract

b/tsDMARDS

Real-world data

remission

rheumatoid arthritis

Objective To describe the trends in remission rates among RA patients in the OPAL dataset, spanning from 2009 to 2022, and provide insights into the effectiveness of evolving RA management approaches in real-world clinical settings. Methods Patients with a physician diagnosis of RA and at least 3 visits between 1 January 2009 and December 2022 were identified in the OPAL dataset, an aggregated collection of data extracted from the electronic medical records of patients managed by 117 Australian rheumatologists. Demographics, disease history, prescribed medications and proportions of patients in Disease Activity Score 28-joint count C-reactive protein (DAS28CRP)) categories (remission, low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA)) were described. Results A large population (n = 48,388) of eligible patients with RA were identified in the OPAL dataset. A consistent and substantial improvement in DAS28CRP remission rates were found in (i) all patients, (ii) patients managed on conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and (iii) patients treated with biological or targeted synthetic (b/ts)DMARD therapy, increasing from approximately 50% in 2009 to over 70% by 2022. The increase in DAS28CRP remission was accompanied by reduced proportions of patients in MDA and HDA states. Conclusion This study highlights a consistent improvement in disease activity and rising remission rates among Australian RA patients within the OPAL dataset, offering the potential for enhanced patient outcomes and reduced disease burden.

Details

Title: Optimising patient outcomes: temporal trends in remission rates of rheumatoid arthritis patients in the Australian OPAL dataset between 2009 and 2022
Authors: Geoffrey Littlejohn (Corresponding Author) - Monash University
Nithila Anbumurali - OPAL Rheumatology Ltd. (Australia)
Catherine O'Sullivan - OPAL Rheumatology Ltd. (Australia)
Tegan Smith - OPAL Rheumatology Ltd. (Australia)
Kathleen Tymms - OPAL Rheumatology Ltd. (Australia)
Paul Bird - UNSW Australia
David Nicholls - University of the Sunshine Coast, Queensland, UniSC Clinical Trials Centre
Hedley Griffiths - Barwon Rheumatology Service (Australia, Victoria)
Publication details: Clinical Rheumatology, Vol.43, pp.1823-1832
Publisher: Springer UK
Date published: 2024
DOI: 10.1007/s10067-024-06967-8
ISSN: 1434-9949
PMID: 38634966; PMC11111498
Copyright note: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Data Availability: Data collection is based on opt-out patient consent, and patients have consented to their data being made available to OPAL Rheumatology only. Requests for access to summary statistics will be considered by the OPAL Scientific Review Committee.
Organisation Unit: UniSC Clinical Trials Centre
Language: English
Record Identifier: 991022798102621
Output Type: Journal article

Metrics

102 File views/ downloads

33 Record Views

1 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Web Of Science research areas: Rheumatology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: SDGs from InCites